Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ROIV Roivant Sciences Ltd.

Closed 01-09 16:00:00 EST

21.98

+0.20

+0.92%

盘后21.98

+0.000.00%

19:55 EST

High22.53	Low21.92	Vol5.26M
Open22.06	D1 Closing21.78	Amplitude2.80%
Mkt Cap15.29B	Tradable Cap9.11B	Total Shares695.49M
T/O116.63M	T/O Rate1.27%	Tradable Shares414.56M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ROIV","market":"US","secType":"STK","nameCN":"Roivant Sciences Ltd.","latestPrice":21.98,"timestamp":1767992400000,"preClose":21.78,"halted":0,"volume":5260146,"hourTrading":{"tag":"盘后","latestPrice":21.98,"preClose":21.98,"latestTime":"19:55 EST","volume":23071,"amount":507092.67,"timestamp":1768006552658},"delay":0,"floatShares":414556768,"shares":695491615,"eps":-0.535859,"marketStatus":"Closed","change":0.2,"latestTime":"01-09 16:00:00 EST","open":22.06,"high":22.53,"low":21.92,"amount":116627320.634334,"amplitude":0.028007,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.535859,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768208400000},"marketStatusCode":5,"adr":0,"listingDate":1607403600000,"exchange":"NASDAQ","adjPreClose":21.78,"preHourTrading":{"tag":"盘前","latestPrice":21.95,"preClose":21.78,"latestTime":"09:27 EST","volume":1667,"amount":36481.948264,"timestamp":1767968830022},"postHourTrading":{"tag":"盘后","latestPrice":21.98,"preClose":21.98,"latestTime":"19:55 EST","volume":23071,"amount":507092.67,"timestamp":1768006552658},"volumeRatio":0.778467,"impliedVol":0.4947,"impliedVolPercentile":0.9044},"requestUrl":"/m/hq/s/ROIV","defaultTab":"news","newsList":[{"id":"2601835368","title":"What Roivant Sciences (ROIV)'s Accelerated Brepocitinib Push Means For Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2601835368","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601835368?lang=en_us&edition=fundamental","pubTime":"2026-01-08 14:29","pubTimestamp":1767853762,"startTime":"0","endTime":"0","summary":"In early January 2026, Roivant Sciences received upbeat analyst commentary on its immunology pipeline while announcing faster development timelines for brepocitinib, including an accelerated New Drug Application in dermatomyositis and Phase III data for non-infectious uveitis now expected in the second half of 2026.\nThe emphasis on brepocitinib’s safety profile and the possibility of additional cutaneous sarcoidosis uses not yet modeled by analysts adds an extra layer of optionality to...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/what-roivant-sciences-roivs-accelerated-brepocitinib-push-me","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/what-roivant-sciences-roivs-accelerated-brepocitinib-push-me","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4007","ROIV"],"gpt_icon":0},{"id":"2600908851","title":"Roivant Sciences President & CIO Mayukh Sukhatme Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2600908851","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600908851?lang=en_us&edition=fundamental","pubTime":"2026-01-01 10:01","pubTimestamp":1767232884,"startTime":"0","endTime":"0","summary":"Mayukh Sukhatme, President & CIO of Roivant Sciences Ltd., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 31, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260101:nNDL8lxYLF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Roivant Sciences President & CIO Mayukh Sukhatme Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","ROIV"],"gpt_icon":0},{"id":"1100480423","title":"Jefferies Sets $24 Price Target for Roivant (ROIV.US), Highlights Three Key 2026 Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=1100480423","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100480423?lang=en_us&edition=fundamental","pubTime":"2025-12-31 14:45","pubTimestamp":1767163541,"startTime":"0","endTime":"0","summary":"Jefferies has published an in-depth research report focusing on the investment outlook for biotechnology firm Roivant Sciences Ltd. (ROIV.US), revealing its three core future catalysts and valuation...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ROIV","BK4139"],"gpt_icon":0},{"id":"2595757545","title":"Roivant Sciences CFO Richard Pulik Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2595757545","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595757545?lang=en_us&edition=fundamental","pubTime":"2025-12-30 10:00","pubTimestamp":1767060057,"startTime":"0","endTime":"0","summary":"Richard Pulik, Chief Financial Officer of Roivant Sciences Ltd., reported a disposal of common shares of Roivant Sciences Ltd. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 29, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nNDL9ScDXV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Roivant Sciences CFO Richard Pulik Reports Disposal of Common Shares","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","BK4139","BK4007"],"gpt_icon":0},{"id":"2595175737","title":"Roivant Sciences President and Immunovant CEO Eric Venker Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2595175737","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595175737?lang=en_us&edition=fundamental","pubTime":"2025-12-30 10:00","pubTimestamp":1767060055,"startTime":"0","endTime":"0","summary":"Eric Venker, President & Immunovant CEO, reported a disposal of common shares of Roivant Sciences Ltd. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 29, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nNDL2S0JgB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4588","BK4139","ROIV","IMVT","BK4585"],"gpt_icon":0},{"id":"2594529434","title":"Insider Confidence In December 2025's Leading Growth Companies","url":"https://stock-news.laohu8.com/highlight/detail?id=2594529434","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594529434?lang=en_us&edition=fundamental","pubTime":"2025-12-26 19:05","pubTimestamp":1766747151,"startTime":"0","endTime":"0","summary":"As the U.S. stock market continues to reach new heights, with the S&P 500 setting an all-time high and major indices logging consecutive gains, investors are increasingly attracted to companies that demonstrate robust growth potential and strong insider confidence. In this thriving environment, stocks with high insider ownership often signal a deep commitment from those who know the company best, suggesting alignment with shareholder interests and potential resilience in times of market...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/insider-confidence-in-december-2025s-leading-growth-companie","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/insider-confidence-in-december-2025s-leading-growth-companie","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4608","IE00B894F039.SGD","BK4532","ROIV","BK4007","BK4555","BK4607","BK4613","LU0605514214.HKD","LU2063271972.USD","LU2065170008.USD","LU0231459107.USD","LU0719512351.SGD","ATAT","BK4096","LU2087625088.SGD","LU1861220033.SGD","NET","LU2931357623.SGD","BK4585","STUB","BK4588","HNGE","BK4199","LU0650527681.SGD","BK4023","LU1852331112.SGD","LU2360106780.USD","LU2360107168.USD","BK4192","LU0097036916.USD","BK4142","LU2290526834.HKD","BK4196","IE00B19Z9P08.USD","BK4107","LU1559883803.SGD","BK4141","LU1861215975.USD","LU2065169927.USD","LU0594300419.USD","LU2065171402.SGD","LU0594300179.USD","LU0274383776.USD","LU2065171311.SGD","NIU","BK4139","SMCI","BK4091","IE0009354923.USD","IE00B19Z9Z06.USD","BK4116","BK4560","LU0056508442.USD","LU0082616367.USD","BK4539","LU0353189763.USD","CORT","IE00BZ9MQY76.HKD","LU0566484027.USD","LU2089985449.USD","LU2286300806.USD","LU2460026573.USD","BK4548","SES","LU0053671581.USD","BK4554","LU2250418816.HKD","NP","BK4543","BK4603","BK4170","LU0353189680.USD","BK4108","BK4558"],"gpt_icon":1},{"id":"2592184119","title":"Roivant Sciences President & CIO Mayukh Sukhatme Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592184119","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592184119?lang=en_us&edition=fundamental","pubTime":"2025-12-20 10:05","pubTimestamp":1766196324,"startTime":"0","endTime":"0","summary":"Mayukh Sukhatme, President & CIO of Roivant Sciences Ltd., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 19, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251220:nNDL8RvD55:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Roivant Sciences President & CIO Mayukh Sukhatme Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ROIV","BK4007"],"gpt_icon":0},{"id":"2592133277","title":"Director Daniel Allen Gold Reports Disposal of Roivant Sciences Ltd. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592133277","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592133277?lang=en_us&edition=fundamental","pubTime":"2025-12-19 08:54","pubTimestamp":1766105698,"startTime":"0","endTime":"0","summary":"Daniel Allen Gold, Director, reported a disposal of common shares of Roivant Sciences Ltd. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 18, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDLbdkmXN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","BK4007","BK4139"],"gpt_icon":0},{"id":"2592613311","title":"QVT Financial LP Reports Disposal of Roivant Sciences Ltd. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592613311","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592613311?lang=en_us&edition=fundamental","pubTime":"2025-12-19 08:42","pubTimestamp":1766104942,"startTime":"0","endTime":"0","summary":"QVT Financial LP reported a disposal of common shares of Roivant Sciences Ltd. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 18, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL2smmKl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"QVT Financial LP Reports Disposal of Roivant Sciences Ltd. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","ROIV"],"gpt_icon":0},{"id":"2592928959","title":"Roivant Sciences CEO Matthew Gline Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592928959","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592928959?lang=en_us&edition=fundamental","pubTime":"2025-12-18 10:00","pubTimestamp":1766023242,"startTime":"0","endTime":"0","summary":"Matthew Gline, CEO and Director of Roivant Sciences Ltd., reported a disposal of common shares of Roivant Sciences Ltd. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 17, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL4PnHpG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Roivant Sciences CEO Matthew Gline Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","BK4007","BK4139"],"gpt_icon":0},{"id":"2592493970","title":"Roivant Sciences (ROIV): Reassessing Valuation After Bullish Pipeline and Patent Milestone Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2592493970","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592493970?lang=en_us&edition=fundamental","pubTime":"2025-12-17 01:14","pubTimestamp":1765905284,"startTime":"0","endTime":"0","summary":"Roivant Sciences (ROIV) just tightened the roadmap on several key assets, updating investors on accelerated timelines for brepocitinib, steady mosliciguat progress, and clearer milestones in its high profile mRNA patent battles.\nSee our latest analysis for Roivant Sciences.\nThose pipeline accelerations seem to be resonating with investors, with Roivant’s share price at $21.9 after an 81.29 percent year to date share price return and a 208.89 percent three year total shareholder return,...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/roivant-sciences-roiv-reassessing-valuation-after-bullish-pi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/roivant-sciences-roiv-reassessing-valuation-after-bullish-pi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ROIV","BK4112","BK4139","BK4007"],"gpt_icon":0},{"id":"2591367127","title":"Vivek Ramaswamy Reports Disposal of Roivant Sciences Ltd. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2591367127","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591367127?lang=en_us&edition=fundamental","pubTime":"2025-12-16 10:35","pubTimestamp":1765852536,"startTime":"0","endTime":"0","summary":"Vivek Ramaswamy, a 10% owner of Roivant Sciences Ltd., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 15, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDL8k0rFH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Vivek Ramaswamy Reports Disposal of Roivant Sciences Ltd. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ROIV","BK4007"],"gpt_icon":0},{"id":"2591962143","title":"Roivant Sciences Is Maintained at Outperform by Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2591962143","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591962143?lang=en_us&edition=fundamental","pubTime":"2025-12-16 04:59","pubTimestamp":1765832340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ROIV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 15, 2025 15:59 ET (20:59 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","BK4139","BK4007"],"gpt_icon":0},{"id":"2591688953","title":"Roivant Sciences Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2591688953","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591688953?lang=en_us&edition=fundamental","pubTime":"2025-12-13 00:31","pubTimestamp":1765557060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ROIV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 12, 2025 11:31 ET (16:31 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","ROIV"],"gpt_icon":0},{"id":"2590504662","title":"Roivant Sciences Ltd. : H.c. Wainwright Raises Target Price to $26 From $23","url":"https://stock-news.laohu8.com/highlight/detail?id=2590504662","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590504662?lang=en_us&edition=fundamental","pubTime":"2025-12-12 22:03","pubTimestamp":1765548209,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nAZN4RDLMM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","ROIV"],"gpt_icon":0},{"id":"2590525707","title":"Roivant Sciences President and Immunovant CEO Eric Venker Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590525707","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590525707?lang=en_us&edition=fundamental","pubTime":"2025-12-12 10:00","pubTimestamp":1765504852,"startTime":"0","endTime":"0","summary":"Eric Venker, President & Immunovant CEO, reported a disposal of common shares of Roivant Sciences Ltd. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 11, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL2Z1sQb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","IMVT","BK4588","BK4585","ROIV"],"gpt_icon":0},{"id":"2590545151","title":"Roivant Signals Major Pipeline Momentum With Accelerated Timelines","url":"https://stock-news.laohu8.com/highlight/detail?id=2590545151","media":"Benzinga_recent_news","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590545151?lang=en_us&edition=fundamental","pubTime":"2025-12-12 02:39","pubTimestamp":1765478340,"startTime":"0","endTime":"0","summary":"Roivant (NASDAQ: ROIV) outlined accelerated timelines and expanded commercial ambitions for several late-stage programs.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/11/biotech-lab.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/11/biotech-lab.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/12/49344150/roivant-signals-major-pipeline-momentum-with-accelerated-timelines","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/12/49344150/roivant-signals-major-pipeline-momentum-with-accelerated-timelines","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4551","BK4555","BK4501","DM","GD","BK4566","ROIV","BK4187","BK4139","BK4550","BK4516","BK4558","BK4585","BK4548","BK4161","BK4546","BK4532","LU0170899867.USD","BK4588","BK4007","IMVT","BK4568","MRNA","BK4091","NIU","BK4534","BK4533"],"gpt_icon":0},{"id":"2590511175","title":"Roivant Sciences Fast-Tracks Key Drug Development Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2590511175","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590511175?lang=en_us&edition=fundamental","pubTime":"2025-12-11 22:11","pubTimestamp":1765462310,"startTime":"0","endTime":"0","summary":"Roivant Sciences  said Thursday it has fast-tracked four of its key drug development programs.The new drug application filing for Brepocitinib in dermatomyositis is now expected early next year, with a commercial launch expected in early 2027. The company said its phase 3 trial for the drug candidate in non-infectious uveitis is fully enrolled, with topline data now expected in H2 2026.Meanwhile, the Brepocitinib proof-of-concept trial in cutaneous sarcoidosis is fully enrolled, with topline data expected in H1 2026.For the IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis, topline data are now expected next year, the company said.Roivant also said it led a funding round for Immunovant  that garnered gross proceeds of around $550 million. The funding will extend Immunovant's cash runway to the launch of IMVT-1402 in Graves' disease.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ROIV","BK4588","BK4007","BK4585","IMVT","BK4139"],"gpt_icon":0},{"id":"2590513028","title":"BRIEF-Roivant Highlights Continued Pipeline Progress And Outlook For Company’S Next Phase Of Growth At 2025 Investor Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2590513028","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590513028?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:38","pubTimestamp":1765456684,"startTime":"0","endTime":"0","summary":"BRIEF-Roivant Highlights Continued Pipeline Progress And Outlook For Company’S Next Phase Of Growth At 2025 Investor DayDec 11 (Reuters) - Roivant Sciences Ltd ROIV.O:ROIVANT HIGHLIGHTS CONTINUED PIPE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA17ZN0Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ROIV","BK4139"],"gpt_icon":0},{"id":"2590251376","title":"Roivant Sciences Hosts Investor Day to Unveil Pipeline Progress and Growth Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2590251376","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590251376?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:30","pubTimestamp":1765456212,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd. will host an Investor Day in New York City at 8:00 a.m. ET on Thursday, December 11, 2025. The event will feature key pipeline updates and provide an overview of the company's long-term strategy for value creation. A live webcast of the event will be available for those unable to attend in person.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire  on December 11, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL5YD2dt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","NDAQ","LU2095319765.USD","ROIV","BK4007","BK4585","IE00BKPKM429.USD","SG9999014021.USD","IE00BGHQF748.EUR","SG9999014039.USD","BK4588","IE00B3QW5Z07.USD","LU2210149790.SGD","LU0314104364.USD","SG9999014005.SGD","IE00B64PRP62.GBP","SG9999014013.SGD","BK4112","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://roivant.com;investor.roivant.com","stockEarnings":[{"period":"1week","weight":0.0037},{"period":"1month","weight":0.0661},{"period":"3month","weight":0.3579},{"period":"6month","weight":0.9173},{"period":"1year","weight":0.9764},{"period":"ytd","weight":0.0037}],"compareEarnings":[{"period":"1week","weight":0.0111},{"period":"1month","weight":0.0095},{"period":"3month","weight":0.0559},{"period":"6month","weight":0.1057},{"period":"1year","weight":0.1697},{"period":"ytd","weight":0.0111}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.07033},{"month":2,"riseRate":0.2,"avgChangeRate":-0.004587},{"month":3,"riseRate":0,"avgChangeRate":-0.096551},{"month":4,"riseRate":0.8,"avgChangeRate":0.019894},{"month":5,"riseRate":0.4,"avgChangeRate":0.032328},{"month":6,"riseRate":0.8,"avgChangeRate":0.015077},{"month":7,"riseRate":0.8,"avgChangeRate":0.040575},{"month":8,"riseRate":0.6,"avgChangeRate":0.00833},{"month":9,"riseRate":0.4,"avgChangeRate":0.013102},{"month":10,"riseRate":0.6,"avgChangeRate":0.101456},{"month":11,"riseRate":0.8,"avgChangeRate":0.02515},{"month":12,"riseRate":0.8,"avgChangeRate":0.23185}],"exchange":"NASDAQ","name":"Roivant Sciences Ltd.","nameEN":"Roivant Sciences Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Roivant Sciences Ltd.(ROIV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Roivant Sciences Ltd.,ROIV,Roivant Sciences Ltd.股票,Roivant Sciences Ltd.股票老虎,Roivant Sciences Ltd.股票老虎国际,Roivant Sciences Ltd.行情,Roivant Sciences Ltd.股票行情,Roivant Sciences Ltd.股价,Roivant Sciences Ltd.股市,Roivant Sciences Ltd.股票价格,Roivant Sciences Ltd.股票交易,Roivant Sciences Ltd.股票购买,Roivant Sciences Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Roivant Sciences Ltd.(ROIV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction